First-in-Human Study of the ATR Inhibitor Tuvusertib as Monotherapy for Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Clin. Cancer Res 2024 Feb 26;[EPub Ahead of Print], TA Yap, AW Tolcher, R Plummer, JK Mukker, M Enderlin, C Hicking, T Grombacher, G Locatelli, Z Szucs, I Gounaris, JS de BonoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.